Ponatinib

Generic Name
Ponatinib
Brand Names
Iclusig
Drug Type
Small Molecule
Chemical Formula
C29H27F3N6O
CAS Number
943319-70-8
Unique Ingredient Identifier
4340891KFS
Background

Ponatinib is a novel Bcr-Abl tyrosine kinase inhibitor that is especially effective against the T315I mutation for the treatment of chronic myeloid leukemia. FDA approved on December 14, 2012.

Indication

1.用于治疗达沙替尼或尼洛替尼治疗无效的慢性期、进展期或急性期的慢性粒细胞白血病（CML）；或不能耐受达沙替尼或尼洛替尼者，以及临床不适合用伊马替尼进行后续治疗的患者；或T315I突变者。

2.用于治疗达沙替尼治疗无效的费城染色体阳性急性淋巴细胞白血病（Ph+ALL）；或不能耐受达沙替尼者，以及临床不适合用伊马替尼进行后续治疗的患者；或T315I突变者。

Associated Conditions
Accelerated Phase Chronic Myelogenous Leukemia (CML), Acute Lymphoblastic Leukaemias (ALL), Chronic Phase Chronic Myeloid Leukemia, Blast phase Chronic myeloid leukemia
Associated Therapies
-
Clinical Trials
Related News

Targeted Therapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia or Acute Myelogenous Leukemia

First Posted Date
2012-06-15
Last Posted Date
2021-11-04
Lead Sponsor
OHSU Knight Cancer Institute
Target Recruit Count
12
Registration Number
NCT01620216
Locations
🇺🇸

OHSU Knight Cancer Institute, Portland, Oregon, United States

Expanded Access Program of Ponatinib

First Posted Date
2012-05-07
Last Posted Date
2018-02-06
Lead Sponsor
Ariad Pharmaceuticals
Registration Number
NCT01592136
Locations
🇺🇸

John Theurer Cancer Center at Hackensack University Medical Center, Site 128, Hackensack, New Jersey, United States

🇺🇸

University of Chicago Medical Center, Site #001, Chicago, Illinois, United States

🇺🇸

Indiana Blood and Marrow Transplantation, Site #138, Indianapolis, Indiana, United States

and more 30 locations

Ponatinib - Frontline for Chronic Myeloid Leukemia (CML) in Accelerated Phase (AP)

Phase 2
Terminated
Conditions
Leukemia
Interventions
Drug: Ponatinib
First Posted Date
2012-04-04
Last Posted Date
2024-06-13
Lead Sponsor
M.D. Anderson Cancer Center
Target Recruit Count
51
Registration Number
NCT01570868
Locations
🇺🇸

University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Compassionate Use Ponatinib

First Posted Date
2012-03-09
Last Posted Date
2013-03-15
Lead Sponsor
OHSU Knight Cancer Institute
Registration Number
NCT01549548
Locations
🇺🇸

OHSU Knight Cancer Institute, Portland, Oregon, United States

Combination Chemotherapy and Ponatinib Hydrochloride in Treating Patients With Acute Lymphoblastic Leukemia

First Posted Date
2011-08-29
Last Posted Date
2024-05-28
Lead Sponsor
M.D. Anderson Cancer Center
Target Recruit Count
88
Registration Number
NCT01424982
Locations
🇺🇸

M D Anderson Cancer Center, Houston, Texas, United States

Ponatinib for Chronic Myeloid Leukemia (CML) Evaluation and Ph+ Acute Lymphoblastic Leukemia (ALL)

First Posted Date
2010-09-23
Last Posted Date
2021-02-02
Lead Sponsor
Ariad Pharmaceuticals
Target Recruit Count
449
Registration Number
NCT01207440
Locations
🇦🇺

Royal North Shore Hospital, St Leonards, New South Wales, Australia

🇩🇪

University of Heidelberg, Mannheim, Germany

🇮🇹

University Tor Vergata, Roma, Italy

and more 39 locations

Safety Study of AP24534 to Treat Chronic Myelogenous Leukemia (CML) and Other Hematological Malignancies

First Posted Date
2008-04-17
Last Posted Date
2018-05-16
Lead Sponsor
Ariad Pharmaceuticals
Target Recruit Count
81
Registration Number
NCT00660920
Locations
🇺🇸

ARIAD Investigational Site #076, Nashville, Tennessee, United States

🇺🇸

ARIAD Investigational Site #005, Houston, Texas, United States

🇺🇸

ARIAD Investigational Site #075, San Francisco, California, United States

and more 2 locations
© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy